Retrospective Analysis of Rifampicin-resistance Pattern of *Mycobacterium tuberculosis* among Presumptive Tuberculosis Patients in Secondary Referral Hospital Offa, Nigeria

Pelumi Daniel Adewole\(^1\)*, Muhammed Usman\(^2\), Maroof Gbadebo Oyeniyi\(^2\), Damilola Kazeem Suleman\(^3\), Olayemi Olubunmi Alaka\(^4\), Ibukun Adeola Adetoro\(^5\) and Olumiyiwa Samuel Alabi\(^6\)

\(^1\)Department of Medical Laboratory Science, School of Basic Medical Science, College of Pure and Applied Sciences, Kwara State University, Malete Kwara State, Nigeria.
\(^2\)General Hospital, Offa, Kwara State, Nigeria.
\(^3\)Department of Medical Laboratory Science, Nigeria Navy School of Health Sciences, Offa, Nigeria.
\(^4\)Department of Medical Microbiology and Parasitoloy, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.
\(^5\)Africa Regional Centre for Information Science, University of Ibadan, Nigeria.
\(^6\)Department of Pharmaceutical Microbioology, Faculty of Pharmacy, University of Ibadan, Nigeria.

**Authors’ contributions**

This work was carried out in collaboration among all authors. Authors PDA and OSA designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors MU and IAA managed the analyses of the study. Authors MGO, DKS and OOA managed the literature searches. All authors read and approved the final manuscript.

**Article Information**

DOI: 10.9734/AJRID/2020/v3i430133

(1) Dr. Hetal Pandya, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, India.

(2) Muhammad Ghafoor Ali, Pakistan.

Complete Peer review History: [http://www.sdiarticle4.com/review-history/56101](http://www.sdiarticle4.com/review-history/56101)

**Received 13 February 2020**

**Accepted 19 April 2020**

**Published 24 April 2020**

**ABSTRACT**

**Introduction:** Early detection of drug resistant tuberculosis with more sensitive and accessible method together with appropriate control measures among other factors are keys to interruption of transmission and mortality rate.
1. INTRODUCTION

Multidrug resistant TB (MDR-TB), defined by *Mycobacterium tuberculosis*, resistant to isoniazid and rifampicin (RIF), the two key first-line anti-TB drugs in short course chemotherapy [1,2]. MDR-TB is an increasing global health problem [3-8]. While MDR-TB develops as a consequence of poor adherence to anti-TB treatment [1,2], Person-to-Person transmission can also occur particularly among health workers (22). The survey based on modeling predicts MDR-TB prevalence in Nigeria to vary from 4.3% (3.2-5.4%) for new cases, 25% (19-31%) for retreated cases [9]. The universal control of tuberculosis is hindered by slow, insensitive diagnostic methods, especially for the identification of drug-resistant forms. Early diagnosis is crucial to lower the mortality rate and hant transmission, but the complexity and infrastructure needs of sensitive methods hinder their accessibility and consequence [1,4]. The common methods of drug resistance testing involve isolation of *M. tuberculosis* on liquid or solid culture medium and with turnaround time of about 8 weeks [1]. Culture methods are time-consuming and expensive consequently reducing both sensitivity and likelihood of prompt treatment for patients [10,11]. Recently, different modern commercial tests based on the genetic sequence have been described for identification of MDR-TB. Example of such is used in the current research for identification of both TB and drug resistant TB [12]. It definitely detects genetic mutations that confer resistance to both isoniazid and rifampicin in patients’ samples. It produces an option to traditional drug sensitivity testing through culture because it is cheap and effective [13,10]. Globally, several locations have used this test successfully with high sensitivity rates for RIF (>95.5%) and isoniazid (>81.8%) resistance [9-16] and 100% specificity [9-16]. Recently, this new nucleic acid amplification diagnostic technologies has attracted much attentions due to their sensitive, specific and swift nature – the Genexpert MTB/RIF. The Xpert assay utilizes, heminested real-time polymerase chain reaction (PCR) to amplify specific rpoB gene of *M. tuberculosis* [17,18]. To detect rifampicin resistance, molecular beacons is used to probe the rifampicin resistance – determining region of rpoB gene is [19]. Therefore, identification of resistance to rifampicin can be accomplished within two hours. The aim of this study is to determine the prevalence of rifampicin resistant TB in our locale using the automated Gene Xpert test system.

2. METHODS

The study was performed in TB Referral Hospital (General Hospital, Offa), located at Southern region of Kwara State. The state covers an area of 36,825 square kilometres. It has a population of 2,365,353 (based on the 2006 census figures). It accounts for 1.69% of Nigeria’s total population [16]. The hospital serves the state, neighboring states and also serves as a referral hospital in the entire Kwara South. All sputum specimens that were submitted to the TB referral hospital laboratory from January to December 2018 of patients who were 4 years and above were included in the study.

**XPERT procedure (MTB/RIF assay):** Sample reagent was added in a 2:1 ratio to untreated sputum and in a 3:1 ratio to decontaminate sputum pellets. The additional sample reagent in
pellets was necessary to meet the volume requirements for the assay sample. The closed sputum container was manually agitated twice during a 15-minute period at room temperature before 2 mL of the inactivated material was transferred to the test cartridge (equivalent to 0.7 mL of untreated sputum or 0.5 mL of decontaminated pellets). Cartridges were inserted into the test platform (Cepheid, Sunnyvale, CA) is an integrated diagnostic device that performs sample processing and heminested real-time polymerase chain reaction (PCR) analysis in a single hands-free step for the diagnosis of tuberculosis and rapid detection of RIF resistance in specimens. The electronic results were sent directly from the MTB/RIF test system to the central database and read after 90 minutes.

2.1 Statistical Analysis

This was by sample percentages using Microsoft Excel 2010 for Windows (Redmond, CA, USA).

3. RESULTS

This study included n=597 sputum specimens, all of which were sent to TB Referral Hospital (General Hospital, Offa)between January to December 2018. Altogether, 63 (10.6%) of the sputum samples collected were positive for M. tuberculosis (Table 1); with 4 (6.3%) showed rifampicin resistance (Table 2). TB appeared to be more prevalent in November with the highest prevalence recorded in December (Fig. 1). In addition, the prevalence of TB and MDR-TB appeared to be increased in > 16 years and above (Fig. 2).

4. DISCUSSION

MDR-TB is TB with bacilli resistant to at least isoniazid and rifampicin, the main anti-tuberculosis drugs. It has become an important concern for TB control in many countries, especially in low-income countries where the burden of other competing diseases like malaria, enteric fever, meningitis and other diseases is high [20,21]. With the advent of the Xpert MTB/RIF testing it is now readily possible to rapidly determine TB bacilli susceptibility to common anti-TB drugs [20,22]. Drug resistant TB develops from the inadequate treatment of active pulmonary TB. There are multiple reasons for inadequate therapy; poor prescribing practices with insufficient treatment duration, far distance between health facilities and patient’s area of resident as well as poor drug selection are well-recognized contributory factors [1,20]. Similarly, Fundamental problems such as; inadequate public health resources, inadequate drug supplies, patient education, adverse events or socio-economic status also contribute. Report has also shown significant number of people acquire drug resistant strain due to location of their residence in high prevalence of drug resistance area [20].

| MTB Positive | Percentage |
|--------------|------------|
| 63           | 10.6       |

| MTB Negative | Percentage |
|--------------|------------|
| 534          | 89.4       |

| Total | 100 |

Table 1. Frequency of M. tuberculosis (MTB) detection by GeneXpert

| Rifampicin sensitive | Frequency | Percentage |
|----------------------|-----------|------------|
| 59                   | 93.7      |

| Rifampicin resistance | Frequency | Percentage |
|-----------------------|-----------|------------|
| 4                     | 6.3       |

| Total | 100 |

Table 2. Frequency of M. tuberculosis (MTB) resistance to Rifampicin

| Male    | Frequency | Percentage |
|---------|-----------|------------|
| 33      | 52.4      |

| Female  | Frequency | Percentage |
|---------|-----------|------------|
| 30      | 47.6      |

| Total   | 100 |

Table 3. Frequency of MTB positive with respect to gender
Using the Xpert MTB/RIF assay system, this study obtained frequency of 6.3% rifampicin mono resistance. This is consistence with the study carried out by Otu A et al., [23] where they attributed low frequency of rifampicin mono-resistance to the new history of use of rifampicin in African countries [24]. Furthermore, our prevalence frequency of 10.6% MTB positive and 6.3% for rifampicin resistance is a good indicator that TB prevalence in Kwara South is very low when compared with studies conducted in Lagos by Adejumo et al., [24] which recorded 37.7% for MTB positive with 23.4% for rifampicin resistance and also lower than 43.3% MTB positive and 17.6% for rifampicin resistance recorded by Kuyinu et al. [25] carried out in Lagos state.

Similarly, our result of 10.6% and 6.3% for MTB positive and rifampicin resistant had further proved the low prevalence of MTB and rifampicin resistance in Kwara South when compared with study carried out in Nasarawa(North Central) by Egbe et al. [26] which reported a prevalence rate of 57.1% for MTB positive while 6.1% was observed for rifampicin resistance and the study
conducted by Ikuabe et al., [27] in Yenogoa (South East) where the prevalence rate stood at 22.9% and 14.7% for both MTB positive rifampicin resistance respectively.

The risk of transmission of TB does not appear to be more in spring and summer in this study as this study observed a progressive increase prevalence of TB and MDR-TB between Novembers to December. This is consistent with work done in Wuhan, China that seasonal variation occurs in the prevalence of pulmonary tuberculosis. This may be due to overcrowding of people in different households in Kwara State during winter, which could lead to an increase in transmission of TB, an observation reported by Xiaobing et al. [28] in a study done in China.

Similarly, age appears to be another important risk factor for TB and Drug Resistance TB as this study examined a progressive increase prevalence of TB for age 16 years and above. This is in agreement with the WHO (2019) report that TB accounts for 89% in >15 years age group.

There is need to strengthen global management of tuberculosis by stepping up efforts in the development of rapid diagnostic test for MDR-TB for the purpose of rapid detection and treatment of MDR-TB. Limitation of this study is that it was carried out only in TB Referral Hospital in General Hospital, Offa and its catchment area. A larger area survey both at national and state level will provide a better estimate of MDR-TB in Nigeria.

There is need to increase the laboratory capacity for rapid detection of MDR-TB in many more zones of the Kwara State and in Nigeria for effective wider coverage. There is also need for this kind of research to be replicated in the remaining two zones (Kwara Central and Kwara North) of the state in order to have a complete and reliable data on MTB in Kwara State.

5. CONCLUSION

There is hope that Mycobacterium tuberculosis can actually be eradicated in Kwara south or reduced to barest minimum. The low frequency of rifampicin resistance also proved that, provided the present cases strictly adhere to their treatment regimen, there is likelihood of achieving low incident of Mycobacterium tuberculosis in Kwara South in the nearest future.

CONSENT

As per international standard or university standard, patient’s written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

This study was approved by the Research and Ethics Committee of the State Ministry of Health.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization. The global MDR-TB & XDR-TB response plan 2007-2008; 2007.
2. World Health Organization. Treatment of tuberculosis: Guidelines. World Health Organization; 2010.
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11):1005-15. [PubMed | Google Scholar]
4. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Curr Opin Infect Dis. 2008;21(6): 587-95. [PubMed | Google Scholar]
5. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010; 48(1):229-37. [PubMed | Google Scholar]
6. Maxmen A. Fighting the monster. Nature. 2010;466(7304):S18-9. [PubMed | Google Scholar]
7. Mário Gajdács, Fernando Albericio. Antibiotic Resistance. From the bench to patients antibiotics. 2019;8(3):129. Available:https://doi.org/10.3390/antibiotics8030129
8. Mário Gajdács. The concept of an ideal antibiotic: Implications for drug design Molecules. 2019;24(5):892. Available:https://doi.org/10.3390/molecules24050892
9. World Health Organisation. Nigeria: Tuberculosis Country profile 2016.
Geneva, Switzerland: World Health Organisation; 2017. [Accessed on 10 december 2017]

10. Adeel Aslam, Márió Gajdács, Che Suraya Zin, Norry Syafiaz Binti Abd Rahman, Syed Imran Ahmed and Shazia Qasim Jamshed. Public awareness and practices towards self-medication with antibiotics among the Malaysian population. A Development of Questionnaire and Pilot-Testing. Antibiotics. 2020;9(2):97. Available:https://doi.org/10.3390/antibiotics9200097

11. World Health Organization. Global TB report 2019. Geneva; 2019. Available:www.who.int/health-topics/tuberculosis#tab=tab

12. Peter OI, Ikema DE. Prevalence of rifampicin resistance by automated genexpert rifampicin assay in Patients with Pulmonary tuberculosis in Yenogoa, Nigeria. Pan African Medical Journal. 2018; 29:204. DOI: 10.1164/pamj. 2018 29.204.14579

13. Bin Li, Yan-Qiu Zhang, Jin Xing, Zhen-Ya Ma, Ya-Hong Qu, Xin-Xu Li. Factors associated with primary transmission of multidrug-resistant tuberculosis compared with healthy controls in Henan Province, China Infectious Diseases of Poverty. 2015; 4:14 DOI: 10.1186/s40249-015-0045-1

14. Causse M, Ruiz P, Gutierrez J, Zerolo J, Casal M. Evaluation of new GenoType® MTBDR plus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis: Int J Tuberc Lung Dis. 2008;12(12):1456-60. [Google Scholar]

15. Huang WL., Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009;47(8):2520-4. [PubMed | Google Scholar]

16. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Roses S, et al. Genotype MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol. 2008;46(11):3660-7.

17. Márió Gajdács, Edit Paulik and Andrea Szabó. Knowledge, attitude and practice of community pharmacists regarding antibiotic use and infectious diseases: A cross-sectional survey in hungary (KAPPhA-HU). Antibiotics. 2020;9(2):41. Available:https://doi.org/10.3390/antibiotics9200041

18. Márió Gajdács, Zoltán Bátori, Marianna Ábrók, Andrea Lázár, Katalin Burián. Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: A 10-year data analysis. Life. 2020;10(2):16. Available:https://doi.org/10.3390/antibiotics1002016

19. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacon. J Clin Microbiol. 2001;39(11):4131-7. [PubMed | Google Scholar]

20. Anek-Vorapong R, Sinthuwattananwibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, et al. Validation of the GenoType® MTBDR plus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis. 2010;10:123. [Google Scholar],

21. City Populations Worldwide. Bayelsa Population; 2017. [Accessed on 10 December 2017]

22. Onyedum CC, Alobu I, Ukwaja KN. Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. PLoS One. 2017;12(7): e0180996. [PubMed | Google Scholar]

23. Otu A, Umoh V, Habib A, Ameh S, Lawson L, Ansa V. Drug resistance among pulmonary tuberculosis patients in Calabar, Nigeria. Pulm Med. 2013;2013: 235190. [PubMed | Google Scholar]

24. Adejumo OA, Olusos-Faley B, Adepoju V, Bowale A, Adesola S, Falana A, Owuna H, Otemuyiwa K, Oladege S, Adegbeye O. Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos, Nigeria. Afr Health Sci. 2018;18(3): 472-478. DOI: 10.4314/ajas.v18i3.2

25. Kuyim YA, Odugbemi BA, Salisu-Olatunji O, Adepoju FO, Odusanya O. Characteristics of Mycobacterium tuberculosis patients screened for drug
26. Egbe K, Ike A, Aleruchi. Prevalence of tuberculosis and rifampicin resistance among patients seeking medical care in Nasarawa State, North central, Nigeria. DOI: 10.11648/j.sjph.20160403.18

27. Peter Ogie Ikuabe, Ikenna Desmond Ebuenyi. Prevalence of rifampicin resistance by automated Genexpert assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. Pan African Medical Journal; 2018. DOI:10.11604/pamj.06/04/2018.29.204.14579

28. Xiaobing Yang, Qionghong Duan, Jianjie Wang, Zhengbin Zhang, Gaofeng Jiang. Seasonal variation of newly notified pulmonary tuberculosis cases from 2004 to 2013 in Wuhan, China. PLoS One. 2014; 9(10):e108369. DOI: 10.1371/journal.pone.0108369 [eCollection 2014]